Lexicon Pharmaceuticals Inc (LXRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH66468D
- Pages: 64
- November 2018
- Total Views:1154
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin (LX4211) for type 1 and type 2 diabetes and its approved product Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome. Lexicon's clinical and preclinical development programs, LX2761 and LX9211 are focused at treating diabetes and neuropathic pain respectively. Lexicon has its laboratory at Texas. It has business collaborations with several pharmaceutical and biotechnology companies. Lexicon is headquartered at The Woodlands, Texas, the US.
Lexicon Pharmaceuticals Inc (LXRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 11
Licensing Agreements 13
Sanofi Amends Licensing Agreement with Lexicon Pharma 13
Lexicon Pharma Expands Licensing Agreement with Ipsen 15
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 16
Equity Offering 18
Lexicon Pharma Files Registration Statement for Public Offering of Shares 18
Lexicon Pharma Raises USD4.7 Million in Private Placement of Shares 19
Lexicon Pharma Raises USD150 Million in Private Placement of Shares 20
Lexicon Pharma Raises USD50 Million in Public Offering of Shares 22
Lexicon Pharma Completes Public Offering Of Common Stock For USD 40 Million 24
Debt Offering 25
Lexicon Pharma Raises USD80 Million in Private Placement of Notes Due 2021 25
Lexicon Pharmaceuticals Inc-Key Competitors 27
Lexicon Pharmaceuticals Inc-Key Employees 28
Lexicon Pharmaceuticals Inc-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 01, 2018: Lexicon Pharmaceuticals reports third quarter 2018 financial results and provides a business update 30
Jul 30, 2018: Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update 32
May 03, 2018: Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business Update 33
Feb 22, 2018: Lexicon Pharmaceuticals Announces Fourth Quarter and Full-year 2017 Financial Results 35
Nov 08, 2017: Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides a Business Update 38
Aug 01, 2017: Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update 39
May 02, 2017: Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update 41
Mar 03, 2017: Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results 43
Product News 45
06/10/2017: Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017 45
06/05/2017: Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions 47
03/29/2018: EMA to Review Sotagliflozin as Potential Treatment for type 1 diabetes 48
03/06/2017: Diplomat to Dispense XERMELO for Patients With Carcinoid Syndrome Diarrhea 49
03/01/2017: XERMELO (telotristat ethyl) Approved for the Treatment of Carcinoid Syndrome, Available for Order Immediately at Biologics 50
02/28/2017: FDA approves Xermelo for carcinoid syndrome diarrhea 51
Product Approvals 52
May 22, 2018: FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes 52
Mar 26, 2018: Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes 53
Clinical Trials 54
Sep 13, 2017: New England Journal of Medicine Publishes Data from Phase 3 inTandem3 Study of Sotagliflozin in Patients with Type 1 Diabetes 54
Sep 08, 2017: Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin 56
Sep 05, 2017: Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting 57
Aug 15, 2017: Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin 58
Jun 09, 2017: Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes 60
May 11, 2017: Lexicon Pharmaceuticals Reports Additional Positive Data from Pivotal InTandem1 Phase 3 Study for Sotagliflozin in Patients with Type 1 Diabetes 61
Jan 09, 2017: Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
List Of Figure
List of Figures
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 11
Sanofi Amends Licensing Agreement with Lexicon Pharma 13
Lexicon Pharma Expands Licensing Agreement with Ipsen 15
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 16
Lexicon Pharma Files Registration Statement for Public Offering of Shares 18
Lexicon Pharma Raises USD4.7 Million in Private Placement of Shares 19
Lexicon Pharma Raises USD150 Million in Private Placement of Shares 20
Lexicon Pharma Raises USD50 Million in Public Offering of Shares 22
Lexicon Pharma Completes Public Offering Of Common Stock For USD 40 Million 24
Lexicon Pharma Raises USD80 Million in Private Placement of Notes Due 2021 25
Lexicon Pharmaceuticals Inc, Key Competitors 27
Lexicon Pharmaceuticals Inc, Key Employees 28
Lexicon Pharmaceuticals Inc, Subsidiaries 29
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Lexicon Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin (LX4211) for type 1 and type 2 diabetes and its approved product Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome. Lexicon's clinical and preclinical development programs, LX2761 and LX9211 are focused at treating diabetes and neuropathic pain respectively. Lexicon has its laboratory at Texas. It has business collaborations with several pharmaceutical and biotechnology companies. Lexicon is headquartered at The Woodlands, Texas, the US.
Lexicon Pharmaceuticals Inc (LXRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 11
Licensing Agreements 13
Sanofi Amends Licensing Agreement with Lexicon Pharma 13
Lexicon Pharma Expands Licensing Agreement with Ipsen 15
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 16
Equity Offering 18
Lexicon Pharma Files Registration Statement for Public Offering of Shares 18
Lexicon Pharma Raises USD4.7 Million in Private Placement of Shares 19
Lexicon Pharma Raises USD150 Million in Private Placement of Shares 20
Lexicon Pharma Raises USD50 Million in Public Offering of Shares 22
Lexicon Pharma Completes Public Offering Of Common Stock For USD 40 Million 24
Debt Offering 25
Lexicon Pharma Raises USD80 Million in Private Placement of Notes Due 2021 25
Lexicon Pharmaceuticals Inc-Key Competitors 27
Lexicon Pharmaceuticals Inc-Key Employees 28
Lexicon Pharmaceuticals Inc-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 01, 2018: Lexicon Pharmaceuticals reports third quarter 2018 financial results and provides a business update 30
Jul 30, 2018: Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update 32
May 03, 2018: Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business Update 33
Feb 22, 2018: Lexicon Pharmaceuticals Announces Fourth Quarter and Full-year 2017 Financial Results 35
Nov 08, 2017: Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides a Business Update 38
Aug 01, 2017: Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update 39
May 02, 2017: Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update 41
Mar 03, 2017: Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results 43
Product News 45
06/10/2017: Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017 45
06/05/2017: Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions 47
03/29/2018: EMA to Review Sotagliflozin as Potential Treatment for type 1 diabetes 48
03/06/2017: Diplomat to Dispense XERMELO for Patients With Carcinoid Syndrome Diarrhea 49
03/01/2017: XERMELO (telotristat ethyl) Approved for the Treatment of Carcinoid Syndrome, Available for Order Immediately at Biologics 50
02/28/2017: FDA approves Xermelo for carcinoid syndrome diarrhea 51
Product Approvals 52
May 22, 2018: FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes 52
Mar 26, 2018: Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes 53
Clinical Trials 54
Sep 13, 2017: New England Journal of Medicine Publishes Data from Phase 3 inTandem3 Study of Sotagliflozin in Patients with Type 1 Diabetes 54
Sep 08, 2017: Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin 56
Sep 05, 2017: Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting 57
Aug 15, 2017: Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin 58
Jun 09, 2017: Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes 60
May 11, 2017: Lexicon Pharmaceuticals Reports Additional Positive Data from Pivotal InTandem1 Phase 3 Study for Sotagliflozin in Patients with Type 1 Diabetes 61
Jan 09, 2017: Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
List Of Figure
List of Figures
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 11
Sanofi Amends Licensing Agreement with Lexicon Pharma 13
Lexicon Pharma Expands Licensing Agreement with Ipsen 15
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 16
Lexicon Pharma Files Registration Statement for Public Offering of Shares 18
Lexicon Pharma Raises USD4.7 Million in Private Placement of Shares 19
Lexicon Pharma Raises USD150 Million in Private Placement of Shares 20
Lexicon Pharma Raises USD50 Million in Public Offering of Shares 22
Lexicon Pharma Completes Public Offering Of Common Stock For USD 40 Million 24
Lexicon Pharma Raises USD80 Million in Private Placement of Notes Due 2021 25
Lexicon Pharmaceuticals Inc, Key Competitors 27
Lexicon Pharmaceuticals Inc, Key Employees 28
Lexicon Pharmaceuticals Inc, Subsidiaries 29
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Lexicon Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020